Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CODIACS: Depression Interventions After ACS
NCT01032018Phase 2Completed
- Sponsor
- Columbia University
- Start
- Jan 2010
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sertraline, citalopram and bupropion in major depressive disorder (MDD) (2 arms), sponsored by Columbia University. Primary endpoints: Depressive Symptom Reduction at 6 months and Cost for Healthcare Utilization at 6 months. Started Jan 2010; status: completed.
02
Drugs
sertralinecitaloprambupropion
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01032018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01032018.